🔗 Share this article

Given that the US proceeds with sweeping changes to its vaccination schedules, a particular individual has surfaced somewhat surprisingly: Dr. Tracy Beth Høeg, an American of Danish descent physician and public health researcher who first made her name by casting doubt on COVID-19 shots during the pandemic and has zeroed in on potential deaths following Covid vaccination in her recent position at the Food and Drug Administration.

Scheduled Shifts to Pediatric Vaccine Program

Agency leaders were set to announce sweeping changes to the pediatric vaccination calendar recently, synchronizing the US with the Danish immunization schedule, sources say – a major change that would place the US at odds with much of the world with little proof for benefit. The planned update has been postponed until the next year.

Rather than the top vaccines chief, Tracy Beth Høeg is scheduled to present at the gathering. She was just designated acting director of the FDA’s drug evaluation center, the fifth individual to run the center this year.

Consolidating Power at the Regulatory Body

The acting appointment could signify a tighter collaboration between the pharmaceutical and vaccine centers as Høeg and Prasad consolidate power at the agency – and it signals a greater focus upon dismantling already-approved immunizations at the FDA.

The new acting director has frequently advocated for halting certain pediatric shot schedules in the US in order to be more like the Danish model, a country with nationalized medicine and a number of inhabitants approximately the population of the state of Wisconsin.

So far public appearances, she has continued to focus on vaccines – traditionally the domain of Dr. Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of pharmaceutical oversight.

Concerns Over Background

The appointee has little discernible background in pharmaceutical research, oversight or leadership, which has been standard for past leaders of the CBER. She has worked at the FDA as a senior adviser to the FDA chief and the vaccine center since March.

“It seems she lacks to have the necessary background” for overseeing the pharmaceutical oversight division, stated Jonathan Howard. “She has not conducted a randomized controlled trial. She lacks experience in leading a large organization. She lacks background in drug approvals.”

Former directors of the center would “grasp legal statutes and the underlying principles of pharmaceutical innovation”, commented Janet Woodcock. “Objectively, she lacks the kind of background that previous people who ran CBER have had.”

CDER has an vast workload at the FDA, the former commissioner emphasized.

“The public just zeroes in on the novel medication approvals, but the generic drug division approves numerous off-brand pharmaceuticals. There’s a biosimilars program, over-the-counter program and other areas, and each of these must be supervised,” Woodcock noted. “The area you overlook, that’s the thing that I always told people is going to bite you.”

Additionally, a major leadership element to the job, which manages more than 5,000 employees. “It’s a huge management job, if you do it right,” the former official added.

Response and Disputed Initiatives

In response to inquiries about Høeg’s fitness for the role and whether this assignment indicates greater collaboration among regulatory chiefs on vaccines, a representative said that the “inquiries rely on flawed premises”.

“This background matches the functions of her job,” the spokesperson explained, noting the months Høeg spent guiding the FDA commissioner on “medication safety and oversight research, including computational safety modeling and shot safety tracking”.

As acting director, Dr. Høeg takes over the agency head's new expedited review system, a disputed one-day medication authorization process that reportedly troubled her preceding directors. “By what process are these therapies being picked for this voucher program? Who is making the calls?” Dr. Howard said. “There’s a lot of lack of transparency happening at the regulatory body right now.”

In general, he said, “the Food and Drug Administration seems to be moving towards less stringent regulations of all drugs, with the exception of shots.”

Public Track Record on Vaccines

Concerning immunizations, Dr. Høeg has a more established, if problematic, past, critics have noted. She published a research paper using non-validated public submissions to estimate the rate of myocarditis following COVID-19 vaccination. She consulted for the Florida chief medical officer Joseph Ladapo, who reportedly have modified findings to imply Covid vaccinations are pose a greater threat than they are.

Among her “wish list” for the new government encompassed altering rules for recently developed shots and discontinuing “non-essential” vaccines, she stated following the vote on a audio program. At the agency, Høeg has according to sources floated the idea of excluding young men from obtaining Covid vaccines.

“She is an complete ideologue who commences with her beliefs and tailors the evidence to retrofit the science in a highly disingenuous, dishonest way,” Howard argued.

Consolidating Power and a “Campaign of Retribution”

Dr. Høeg aligned with other contrarians, {like|